Shots:
- Repligen has entered into a definitive agreement to acquire BioLife
- Repligen will acquire BioLife for an enterprise value of ~$1.5B, with BioLife stockholders receiving $11.25 per share in cash plus 0.1442 Repligen shares, representing total consideration of $31/share, comprising 64% stock & 36% cash
- Acquisition is expected to fast-track Repligen’s leadership & customer solutions in the high-growth cell therapy market by adding BioLife’s differentiated, high-margin, recurring-revenue business
Ref: Repligen | Image: BioLife | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
